Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis

Psychopharmacology
Taro KishiNakao Iwata

Abstract

We examined whether memantine add-on to antipsychotic treatment is beneficial in schizophrenia treatment. This systematic review and meta-analysis aimed to achieve stronger evidence on the efficacy and safety of memantine add-on for treating schizophrenia. We analyzed double-blind, randomized, placebo-controlled trials of memantine add-on treatment in schizophrenia patients receiving antipsychotics. The primary outcomes were amelioration of negative symptoms and all-cause discontinuation. Dichotomous outcomes are presented as risk ratios (RRs), and continuous outcomes are presented as mean differences (MDs) or standardized mean differences (SMDs). Eight studies (n = 448) were included. Although memantine add-on treatment was superior to placebo for ameliorating negative symptoms (SMD = -0.96, p = 0.006, I (2) = 88%; N = 7, n = 367) in the Positive and Negative Syndrome Scale general subscale (MD = -1.62, p = 0.002, I (2) = 0%; N = 4, n = 151) and Mini-Mental Status Examination score (MD = -3.07, p < 0.0001, I (2) = 21%; N = 3, n = 83), there were no statistically significant differences in the amelioration of overall (SMD = -0.75, p = 0.06, I (2)  = 86%; N = 5, n = 271), positive (SMD = -0.46, p = 0.07, I (2) = 80%; N = 7, n = ...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jul 1, 1990·Schizophrenia Research·D AddingtonB Schissel
Jul 1, 1983·Archives of General Psychiatry·M F FolsteinJ E Helzer
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Sep 16, 2003·International Journal of Geriatric Psychiatry·Wojciech Danysz, Chris G Parsons
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Dec 23, 2004·Journal of Clinical Epidemiology·Thomas A TrikalinosUNKNOWN EU-PSI project
Nov 4, 2005·Current Drug Targets. CNS and Neurological Disorders·Horst J KochDavid Fischer-Barnicol
Jan 6, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daniel KondziellaUrsula Sonnewald
Jul 10, 2007·Schizophrenia Bulletin·John A Gray, Bryan L Roth
Sep 15, 2007·Schizophrenia Research·Michael A CerulloAmelia T Nasrallah
Oct 27, 2007·Trends in Pharmacological Sciences·Peter K Stys, Stuart A Lipton
Nov 15, 2007·Synapse·Philip SeemanMercedes Lasaga
Feb 12, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Kristina Zdanys, Rajesh R Tampi
Nov 14, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey A LiebermanUNKNOWN MEM-MD-29 Study Group
Jan 14, 2009·BMC Medical Research Methodology·Santiago G MorenoNicola J Cooper
Feb 25, 2009·Expert Opinion on Drug Safety·Harish Kavirajan
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Aug 25, 2009·Lancet·Jim van Os, Shitij Kapur
Aug 16, 2011·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Karen BermanKatrin Seeher
Jun 19, 2013·Frontiers in Psychiatry·Shaheen E LakhanNorell Hadzimichalis
Jan 16, 2014·Journal of Psychiatric Research·Seong S Shim, Rashid Nadeem
May 6, 2014·Physiology & Behavior·Zoran Vukadinovic
Jun 1, 2014·Schizophrenia Research·Maju Mathew KoolaFaith B Dickerson
Jun 27, 2014·Expert Opinion on Therapeutic Targets·Kenji Hashimoto
Jul 17, 2014·The British Journal of Psychiatry : the Journal of Mental Science·Joseph KambeitzOliver D Howes
Apr 22, 2015·The International Journal of Neuropsychopharmacology·Anna HöflichRupert Lanzenberger
Jun 13, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neal R SwerdlowGregory A Light
May 24, 2016·Psychopharmacology·Katherine BeckOliver D Howes
Mar 1, 2017·Journal of Amino Acids·Giuseppe Di IorioMassimo di Giannantonio

❮ Previous
Next ❯

Citations

Oct 19, 2017·Psychopharmacology·Selene VeermanLieuwe de Haan
Oct 17, 2018·Journal of Psychopharmacology·Borja SantosJavier Ballesteros
Nov 1, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·William C HochbergerGregory A Light
Jan 23, 2019·Psychiatry and Clinical Neurosciences·Yota Uno, Joseph T Coyle
Sep 23, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neal R SwerdlowGregory A Light
May 16, 2018·The International Journal of Neuropsychopharmacology·Taro KishiNakao Iwata
Jan 16, 2021·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Kamila CzarneckaPaweł Szymański
Apr 17, 2018·Biological Psychiatry : Cognitive Neuroscience and Neuroimaging·Joshua T KantrowitzSophia Vinogradov
Mar 18, 2021·European Psychiatry : the Journal of the Association of European Psychiatrists·S GalderisiW Gaebel

❮ Previous
Next ❯

Methods Mentioned

BETA
SGA

Software Mentioned

Comprehensive Meta - Analysis
Plus
Review Manager
MINI
Cochrane

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here